Serum amino-terminal pro-brain natriuretic peptide in hematological patients with neutropenic fever: a prospective comparison with C-reactive protein.

abstract：:Granulocytic sarcomas (GS) are rare extra medullary tumors composed of myeloid progenitor cells. Bones, lymph nodes and skin are favored sites of involvement. Primary involvement of the ovary is exceedingly rare leading to under diagnosis of GS. We report on a 19-year-old woman who presented with an ovarian mass witho...

journal_title：Leukemia & lymphoma

authors： Mehta J,Kane S

更新日期：2004-04-01 00:00:00

abstract：:CD30 ligand (CD30L) is a type-II membrane glycoprotein capable of transducing signals through its specific counterstructure CD30. Even though there are indications that CD30L plays a key role as a paracrine-acting surface molecule in the deregulated cytokine cascade of Hodgkin's disease, little is known about its biol...

journal_title：Leukemia & lymphoma

authors： Gattei V,Degan M,Rossi FM,de Iuliis A,Mazzocco FT,Serraino D,Zagonel V,Aldinucci D,Pinto A

更新日期：1999-09-01 00:00:00

abstract：:Ibrutinib is a first-in-class small molecule inhibitor that has shown remarkable efficacy in the treatment of CLL. Current guidelines recommend lifelong administration at a fixed daily dose of 420 mg. Data from real-world studies indicate up to 17.5% of patients discontinue ibrutinib due to toxicity. Hypothetically, j...

journal_title：Leukemia & lymphoma

authors： Akhtar OS,Attwood K,Lund I,Hare R,Hernandez-Ilizaliturri FJ,Torka P

更新日期：2019-07-01 00:00:00

abstract：:An unusual case of aplastic anemia presenting in association with lymphoplasmacytic lymphoma and paroxysmal nocturnal hemoglobinuria is discussed. An insult to the hematological stem cell compartment may result in multiple pathological entities, potentially influencing our approach to the treatment of hematological cl...

journal_title：Leukemia & lymphoma

authors： Veidt RG,Ansari-Lari A,Brodsky RA

更新日期：2005-08-01 00:00:00

abstract：:Our aim was to describe a large population-based cohort of diffuse large B-cell lymphoma (DLBCL) during the last decade, evaluating possible improvement in survival and to identify subgroups in need of novel treatment strategies. The study population encompassed all patients diagnosed with DLBCL in Sweden from 2000 th...

journal_title：Leukemia & lymphoma

authors： Székely E,Hagberg O,Arnljots K,Jerkeman M

更新日期：2014-08-01 00:00:00

abstract：:Lenalidomide is a backbone agent in the treatment of multiple myeloma, but dose adjustment is required for those with renal impairment (RI). We evaluated the pharmacokinetics (PK) and safety of lenalidomide and dexamethasone as frontline pre-transplant induction, with doses adjusted at start of each cycle based on cre...

journal_title：Leukemia & lymphoma

authors： Chen CI,Cao Y,Trudel S,Reece DE,Kukreti V,Tiedemann R,Prica A,Paul H,Le LW,Levina O,Kakar S,Lau A,Chen H,Chen E

更新日期：2020-08-01 00:00:00

abstract：:The aim of this study was to evaluate the frequency of polymorphisms in the TYMS, XRCC1, and ERCC2 DNA repair genes in pediatric patients with acute lymphoblastic leukemia using polymerase chain reaction (PCR) and PCR-restriction fragment length polymorphism (RFLP) approaches. The study was conducted in 206 patients a...

journal_title：Leukemia & lymphoma

authors： Canalle R,Silveira VS,Scrideli CA,Queiroz RG,Lopes LF,Tone LG

更新日期：2011-06-01 00:00:00

abstract：:An analysis by month of diagnosis was made of 1359 cases of Hodgkins disease (HD) on the Scotland and Newcastle Lymphoma Group (SNLG) registry 1979-1992 to look for evidence of seasonality. A March peak was evident when all cases were analysed (p < 0.01). The histological subtypes nodular sclerosing (NS) and mixed cel...

journal_title：Leukemia & lymphoma

authors： Neilly IJ,Dawson AA,Bennett B,Douglas S

更新日期：1995-07-01 00:00:00

abstract：:Although BCR-ABL is the hallmark genetic abnormality of chronic myeloid leukemia (CML), secondary molecular events responsible for the evolution of the disease to blast crisis are yet to be deciphered. Taking into account the significant association of ecotropic viral integration site I (EVI1) in CML drug resistance, ...

journal_title：Leukemia & lymphoma

authors： Kuila N,Nayak KB,Halder A,Agatheeswaran S,Biswas G,Biswas S,Pattnayak NC,Chakraborty S

更新日期：2017-08-01 00:00:00

abstract：:A young man presented with systemic symptoms and marked eosinophilia. Subsequently cyclical weight gain and edema contributed to a diagnosis. ...

journal_title：Leukemia & lymphoma

authors： Marks AJ,Abdalla SH,Cross NC,Bain BJ

更新日期：2006-08-01 00:00:00

abstract：:The purpose of this study was to better define the clinical features and natural history of peripheral T-cell lymphomas (PTCL) entities included in the Revised European American lymphoma (REAL) classification. Cases of PTCL were retrieved from the records of the Department of Pathology and classified according to the ...

journal_title：Leukemia & lymphoma

authors： Arrowsmith ER,Macon WR,Kinney MC,Stein RS,Goodman SA,Morgan DS,Flexner JM,Cousar JB,Jagasia MH,McCurley TL,Greer JP

更新日期：2003-02-01 00:00:00

abstract：:Following the initial success of imatinib as frontline therapy for chronic myeloid leukemia (CML), several second-generation therapeutics have been developed with increased potency and the ability to inhibit the majority of imatinib-resistant mutations. Here, we review the current knowledge about the target specificit...

journal_title：Leukemia & lymphoma

authors： Hantschel O,Rix U,Superti-Furga G

更新日期：2008-04-01 00:00:00

abstract：:To evaluate the prognostic features of Ph+ CML patients treated by allogeneic BMT or by IFN, we reviewed the data of 50 consecutive pts who were transplanted between 1984 and 1988 and of 180 consecutive patients who were assigned to continuous IFN treatment between 1986 and 1988. In the BMT group, Sokal's system predi...

journal_title：Leukemia & lymphoma

authors：

更新日期：1993-01-01 00:00:00

abstract：:The aim of this research was to determine the serum dipeptidyl peptidase IV (DPPIV) activity as well as the percentages of CD26 + lymphocytes and CD26 + overall white blood cells in patients with hematological malignancies: non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), leukemia, plasmacytoma and multiple myeloma,...

journal_title：Leukemia & lymphoma

authors： Matić IZ,Đorđević M,Đorđić M,Grozdanić N,Damjanović A,Kolundžija B,Vidović A,Bila J,Ristić S,Mihaljević B,Tomin D,Milanović N,Ristić D,Purić M,Gavrilović D,Cordero OJ,Juranić ZD

更新日期：2013-12-01 00:00:00

abstract：:Management of early stages of Hodgkin's disease requires development of treatment programs that are nominally toxic, with a low likelihood of sterility and secondary malignancies, both associated with alkylating agents. Although patients with laparotomy-staged disease without B symptoms or large mediastinal masses hav...

journal_title：Leukemia & lymphoma

authors： Hagemeister FB

更新日期：1993-01-01 00:00:00

abstract：:The diagnosis of non-Hodgkin lymphoma (NHL) is increasingly common among the elderly and it is well recognized that this patient population may benefit from therapy. No guidelines exist for chemotherapy dosing in the elderly population, and a clear assessment of treatment toxicity and benefits has not been previously ...

journal_title：Leukemia & lymphoma

authors： Huntington SF,Talbott MS,Greer JP,Morgan DS,Reddy N

更新日期：2012-08-01 00:00:00

abstract：:The role of cyclic AMP (cAMP) as second messenger in erythropoiesis has been suggested in the early 1980s. However, careful analysis showed that cAMP is not generated in direct response to the main erythropoiesis-controlling cytokines such as erythropoietin (Epo). As a result, cAMP disappeared from the central stage i...

journal_title：Leukemia & lymphoma

authors： Boer AK,Drayer AL,Vellenga E

更新日期：2003-11-01 00:00:00

abstract：:CD95 is a cell-surface receptor that mediates apoptosis. A possible association between CD95 mutations and extranodal diffuse large B-cell lymphomas (DLBCL) has been reported. To further elucidate this question, a mutation analysis within the 5' region and exon 9 of CD95 was performed in a series of 66 DLBCL patients,...

journal_title：Leukemia & lymphoma

authors： Scholl V,Stefanoff CG,Hassan R,Spector N,Renault IZ

更新日期：2007-05-01 00:00:00

abstract：:During the last decade, several studies have evaluated the treatment of chronic phase chronic myeloid leukemia (CML) with a combination of interferon (IFN)-alpha and low- dose cytarabine (Ara-C). This combination therapy has been shown to be superior compared to monotherapy with IFN-alpha in randomized studies with re...

journal_title：Leukemia & lymphoma

authors： Lindauer M,Fischer T

更新日期：2001-05-01 00:00:00

abstract：:Arsenic trioxide, believed to be a carcinogen and a teratogen, has found its niche in the treatment of acute promyelocytic leukemia (APL). APL is a disease affecting young patients. Post-treatment fertility and outcome of pregnancy are always a concern in a disease with high cure rates. We report a case series of six ...

journal_title：Leukemia & lymphoma

authors： Gupta S,Bagel B,Gujral S,Subramanian PG,Khattry N,Menon H,Nair R

更新日期：2012-11-01 00:00:00

abstract：:Primary non-Hodgkin's lymphoma of bone is uncommon and usually manifests clinically as localized bone pain. Here we report a woman who presented with hypercalcemic crisis and extensive investigation revealed a primary multifocal lymphoma of bone. The course of the disease was very aggressive and despite intensive supp...

journal_title：Leukemia & lymphoma

authors： Evron E,Goland S,Klepfish A,Malnick SD,Sokolowski N,Sthoeger ZM

更新日期：1999-06-01 00:00:00

abstract：:We and others previously demonstrated that human multiple myeloma (MM) cells express CD40 and have an active CD40-growth regulatory pathway. This study characterizes the growth outcome of soluble (gp39) or membrane-bound recombinant human CD40-ligand (rCD40L) and its relationship with Fas-dependent apoptosis. Contrary...

journal_title：Leukemia & lymphoma

authors： Tong AW,Seamour B,Chen J,Su D,Ordonez G,Frase L,Netto G,Stone MJ

更新日期：2000-02-01 00:00:00

abstract：:Non-malignant host immune cells are the main substrate in classical Hodgkin lymphoma (HL) microenvironment. Reconstitution of lymphocyte populations following the high-dose chemotherapy (HDC) with autologous hematopoietic stem cell transplantation (auto-HSCT) can support tumor growth in HL patients. We investigated re...

journal_title：Leukemia & lymphoma

authors： Batorov EV,Pronkina NV,Tikhonova MA,Kryuchkova IV,Sergeevicheva VV,Sizikova SA,Ushakova GY,Aristova TA,Batorova DS,Shishkova IV,Gilevich AV,Shevela EY,Ostanin AA,Chernykh ER

更新日期：2019-10-01 00:00:00

abstract：:The purpose of this research was to understand the effect of hyperthermia on the telomerase activity in human leukemic cell lines (HL-60, K562, and TF-1). The cells were treated by hyperthermia at the range of 41-44 degrees C for 120 min and incubated for 96 h. Then telomerase activity, cell proliferation, and apoptos...

journal_title：Leukemia & lymphoma

authors： Deezagi A,Manteghi S,Khosravani P,Vaseli-Hagh N,Soheili ZS

更新日期：2009-09-01 00:00:00

abstract：:The importance of obtaining a tumor-free graft for autologous transplantation in cancer patients has been debated extensively in the last decade and is still unresolved largely because it is believed that relapse is more likely to originate from the host and not from the graft. This is in spite of recent indications t...

journal_title：Leukemia & lymphoma

authors： Gazitt Y,Reading CL

更新日期：1996-10-01 00:00:00

abstract：:Expression of T, sialosyl-T and disialosyl-T antigens on normal blood and bone marrow cells as well as transformed cells was examined using specific monoclonal antibodies and multidimensional flow cytometry. Both anti-sialosyl-T (QSH1) and anti-disialosyl-T (QSH2) monoclonal antibodies aggregated erythrocytes. The ant...

journal_title：Leukemia & lymphoma

authors： Muroi K,Amemiya Y,Sievers EL,Miura Y,Hakamori SI,Loken MR

更新日期：1997-05-01 00:00:00

abstract：:The V617F mutation of the JAK2 tyrosine kinase is found in a majority of patients with myeloproliferative disorders. Flow cytometry assays for quantitation of phosphorylated and total protein for JAK2, STAT5, and heat shock proteins (HSPs) were developed to facilitate the study of the JAK/STAT pathway. A cell line hom...

journal_title：Leukemia & lymphoma

authors： Bareng J,Jilani I,Gorre M,Kantarjian H,Giles F,Hannah A,Albitar M

更新日期：2007-11-01 00:00:00

abstract：:Chronic myeloid leukemia therapy has remarkably improved with the use of frontline BCR-ABL kinase inhibitors such that newly diagnosed patients have minimal disease manifestations or progression. Effective control of disease may also set the stage for eventual 'cure' of this leukemia. However, the existence of Philade...

journal_title：Leukemia & lymphoma

authors： Donato NJ,Peterson LF

更新日期：2011-02-01 00:00:00

abstract：:In this report, we present a patient with chronic myeloid leukemia (CML) in blastic phase who had two consecutive episodes of spontaneous regression back to chronic phase without chemotherapy. Although, spontaneous remission (SR) is well documented in acute leukemia, SR in CML blastic phase is extremely rare and to th...

journal_title：Leukemia & lymphoma

authors： Cağirgan S,Sencan M,Tombuloglu M,Ozdemir E,Hekimgil M,Büyükkeçeci F

更新日期：1998-04-01 00:00:00

abstract：:The tyrosine kinase inhibitors (TKIs), nilotinib, ponatinib, and dasatinib (but not bosutinib or imatinib), are associated with vascular adverse events (VAEs) in chronic myeloid leukemia (CML). Though the mechanism is inadequately understood, an effect on vascular cells has been suggested. We investigated the effect o...

journal_title：Leukemia & lymphoma

authors： Gover-Proaktor A,Granot G,Pasmanik-Chor M,Pasvolsky O,Shapira S,Raz O,Raanani P,Leader A

更新日期：2019-01-01 00:00:00